GEN Exclusives

More »

Best of the Web

More »
May 01, 2007 (Vol. 27, No. 9)

The Carcinogenic Potency Project (CPDB)

URL:potency.berkeley.edu
  • Wide spanning information
  • None
If you feel like you hit the jackpot when you visit the Carcinogenic Potency Project site, you’re probably interested in cancer-causing chemicals. The jackpot you’ll realize contains the results of 6,153 (at press time) chronic, long-term animal cancer tests on 1,485 chemicals. Yum! This truly is an awesome collection, and the information is nicely organized. The opening page divides content into 16 areas, ranging from a summary of chemical structures of compounds in the database to numerous tables of data. The latter includes summaries of target sites, dosing/survival, and a ranking of cancer hazards based on rodent data. I was intrigued by one entire category devoted to aristolochic acid, a component in numerous herbal products sold on the web for weight loss, but linked to urothelial carcinoma. Amazingly enough (or maybe not so), the FDA issued warnings about the compound in 2001, but by 2003, the materials were still for sale! If you go to the site, you can read the letter from Lois Gold and Thomas Slone to the FDA on this matter. After reading this, I have to wonder what good the FDA is if it cannot act on its own warnings.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?